USP boosts support for AAV-based gene therapy manufacturers
Alongside publication of the proposed General Chapter < 1067 >, the new resources from USP aim to help advance AAV gene therapies.
List view / Grid view
Alongside publication of the proposed General Chapter < 1067 >, the new resources from USP aim to help advance AAV gene therapies.
This article explores how artificial intelligence (AI) is forming an essential pillar of staying competitive in pharmaceutical manufacturing, with its adoption ensuring greater efficiency of medicine production in this fast-evolving sector.
The research provides insight into effective measurement of particle adhesion, potentially enhancing pharmaceutical powder processing.
11 April 2025 | By European Pharmaceutical Review
Join this webinar for expert insights from scientists and subject matter experts on the key trends shaping the pharmaceutical manufacturing sector.
CPI’s strategy will help pharmaceutical industry partners to accelerate digitalisation of the pharmaceutical manufacturing process.
Colleagues from biopharmaceutical company MSD reveal what it takes to fully realise the benefits of PAT implementation.
The licensing agreement will support development of medicines for delivery across the blood-brain barrier to treat neurological disorders like Alzheimer’s and Parkinson’s.
Ensuring the quality, safety and efficacy of new pharmaceutical products is critical to bring them to market successfully. Here, Adragos Pharma’s Amalia Stroumpou, explains how the key to all three of these factors is rigorous good manufacturing practice (GMP) analytical testing.
The research highlights that major barriers to digital innovation in life sciences include cultural attitudes on AI’s potential, governance and digital skills.
The approach offers key benefits such as facilitating a reduction in the risk of microbial contamination and reduction in the required air change rate in aseptic processing.
Dave Elder reflects on the array of applications for AI to facilitate successful drug development, though proof remains elusive.
The proposed approach demonstrates benefit for real-world application, establishing more robust, adaptive, and economical process systems, the research suggests.
EPR's latest Pharma Horizons report explores the latest advances in artificial intelligence (AI) for drug and clinical development, regulation and more.
Addressing key challenges in the pharmaceutical and biotechnology environmental monitoring market, such as high technology costs, while leveraging key market drivers is critical for the sector to thrive, analysis suggests.
The proposed technique outperformed traditional controllers, supporting improved air quality control in cleanrooms, according to the study.